Fluoroazomycin arabinoside clinical trials
Also written 18F-FAZA.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses fluoroazomycin arabinoside is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Other names
- 18F-FAZA
- 2
Studies by the year they started
4 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test fluoroazomycin arabinoside.
- Jun 202718F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung CancerNot applicable · University Health Network, Toronto
Studies
Open first, then newest update. How each study uses fluoroazomycin arabinoside is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- FAZA PET/MRI SarcomaActive, not recruitingNot applicableUniversity Health Network, TorontoNCT03418818Written as 18F-FAZA
- 18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung CancerActive, not recruitingNot applicableUniversity Health Network, TorontoNCT02701699Written as 18-F-FAZA
- Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET/CT TracersCompletedPhase 2Institut CurieNCT02802969Written as 18F FAZA
- A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 PlaceboWithdrawnNot applicableUniversity Health Network, TorontoNCT02496832Written as 18F-Fluoroazomycin arabinoside
Given beside what is tested · 1 — fluoroazomycin arabinoside is usual care or a partner of the new treatment
Codes
What other systems call fluoroazomycin arabinoside · ClinicalTrials.gg INT004751
- MeSH (NLM) C498052fluoroazomycin arabinosideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1QR3UU6P48FLUOROAZOMYCIN ARABINOSIDEConfirmed NLM, Wikidata
- Wikidata Q27252764fluoroazomycin arabinosideConfirmed NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C498052 | fluoroazomycin arabinoside | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1QR3UU6P48 | FLUOROAZOMYCIN ARABINOSIDE | Confirmed NLM, Wikidata |
| Wikidata | Q27252764 | fluoroazomycin arabinoside | Confirmed NLM, Wikidata |
Also registered as fluoroazomycin arabinoside f-18 (UNII UG7I3Y42PV).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.